期刊文献+

血清CC型修饰趋化因子11和膜联蛋白A2水平变化与胃癌患者临床分期的相关性 被引量:1

原文传递
导出
摘要 目的探究血清CC型修饰趋化因子11(CCL11)和膜联蛋白A2(ANXA2)水平变化与胃癌患者临床分期的相关性。方法选取2017年5月至2019年6月本院收治的86例胃癌患者为胃癌组,选取同期胃部良性疾病患者86例为良性组,选取体检中心健康体检者86例为对照组。比较各组及不同年龄、性别、病灶直径、分化程度、临床分期胃癌患者血清CCL11、ANXA2水平,采用Pearson分析血清CCL11、ANXA2水平与分化程度、临床分期的相关性。结果胃癌组血清CCL11和ANXA2水平高于良性组、对照组,差异均有统计学意义(均P<0.05);良性组血清CCL11水平为(40.82±10.16)pg/ml,高于对照组,差异有统计学意义(P<0.05)。中低分化程度胃癌患者血清CCL11和ANXA2水平高于高分化患者,临床分期Ⅰ、Ⅱ、Ⅲ、Ⅳ期胃癌患者血清CCL11和ANXA2水平依次升高,差异均有统计学意义(均P<0.05)。血清CCL11和ANXA2水平与分化程度均呈负相关,与临床分期均呈正相关(均P<0.05)。结论胃癌患者血清中CCL11、ANXA2水平呈高表达,均与分化程度呈负相关,与临床分期呈正相关,可为临床诊断及分期鉴别评估提供参考。
作者 李超
出处 《中国卫生工程学》 CAS 2020年第2期252-254,共3页 Chinese Journal of Public Health Engineering
  • 相关文献

参考文献9

二级参考文献74

  • 1Chia-Cheng Lin,Ping-Yi Lin,Yao-Li Chen.Comparison of concomitant and subsequent cholangiocarcinomas associated with hepatolithiasis:Clinical implications[J].World Journal of Gastroenterology,2013,19(3):375-380. 被引量:16
  • 2赵玲,崔全才.Annexin A2在肿瘤发生中的作用研究进展[J].中华病理学杂志,2007,36(2):129-132. 被引量:9
  • 3Lauren P.The two histological main types of gastric carcinoma:diffuse and so-called intestinal-type carcinoma.An attempt at a histo-clinical classification.Acta Pathol Microbiol Scand,1965,64:31-49.
  • 4Schlemper R J,Itabeshi M,Kato Y,et al.Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists.Lancet,1997,349(9067):1725-1729.
  • 5Ichikura T,Tomimatsu S,Uefuji K,et al.Evaluation of the New American Joint Committee on Cancer/International Union against cancer classification of lymph node metastasis from gastric carcinoma in comparison with the Japanese classification.Cancer,1999,86(4):553-558.
  • 6Hamilton SR,Aaltonen LA.World Health Organization classification of tumours.Pathology and genetics of turnouts of the digestive system.Lyon:IARC Press,2000.
  • 7Zheng H,Takahashi H,Murai Y,et al.Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan:an immunostaining study on the tissue microarray.J Clin Pathol,2007,60(3):273-277.
  • 8Solcia E,Klersy C,Mastracci L,et al.A combined histo]ogic and molecular approach identifies three groups of gastric cancer with different prognosis.Vircbews Arch,2009,455(3):197-211.
  • 9ZHANG X, XU J, LIU H, et al. Predictive biomarkers for the efficacy of cetuximab combiaed with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective muhicenter phase 2 trial[J]. Med Oncoh2014,31(10) :226.
  • 10HAN K,JIN J,MAIA M,et al. Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase Ill trial [J]. AAPS J, 2014,16 (5) : 1056 -- 1063.

共引文献175

同被引文献11

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部